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Abstract: 
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is a rare autosomal dominant 
inherited peripheral neuropathy caused by mutations in the SPTLC1 and 2 subunits of serine 
palmitoyltransferase (SPT). The mutations induce a permanent shift in the substrate 
preference from L-serine to L-alanine, which results in the pathological formation of atypical 
and neurotoxic 1-deoxy-sphingolipids (1-deoxySL). Here we compared the enzymatic 
properties of eleven SPTLC1 and six SPTLC2 mutants using a uniform isotope labelling 
approach. In total eight SPT mutants (STPLC1p.C133W,p.C133Y,p.S331F,p.S331Y and 
SPTLC2p.A182P,p.G382V,p.S384F,p.I504F) were associated with increased 1-deoxySL 
synthesis. Despite earlier reports, canonical activity with L-serine was not reduced in any of 
the investigated SPT mutants. Three variants (SPTLC1p.S331F/Y and SPTLC2p.I505Y) 
showed an increased canonical activity and increased formation of C20 sphingoid bases. 
These three mutations are associated with an exceptionally severe HSAN1 phenotype, and 
increased C20 sphingosine levels were also confirmed in plasma of patients. A principal 
component analysis of the analyzed sphingoid bases clustered the mutations into three 
separate entities. Each cluster was related to a distinct clinical outcome (no, mild, severe 
HSAN1 phenotype). A homology model based on the protein structure of the prokaryotic SPT 
recapitulated the same grouping on a structural level. Mutations associated with the mild 
form clustered around the active site, whereas mutations associated with the severe form 
were located on the surface of the protein. In conclusion, we showed that HSAN1 mutations 
in SPT have distinct biochemical properties which allowed for the prediction of the clinical 
symptoms based on the plasma sphingoid base profile. 
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Introduction: 
Hereditary sensory and autonomic neuropathies (HSAN) represent a group of neurologic 
disorders with high genotypic and phenotypic variability which affect the peripheral nervous 
system. HSANs have been subdivided into seven classes with distinct phenotypes (Peter 
James Dyck, 1993; Edvardson et al., 2012; Leipold et al., 2013). HSAN type 1 (HSAN1) 
differs from the other forms (HSAN2-7) by its autosomal dominant inheritance (1, 2). It is a 
mutilating, axonal neuropathy typically characterized by a slow and progressive sensory loss 
and the formation of perforating ulcers at the feet and hands. Typically, first clinical 
symptoms appear between the 2nd and 5th decade (1-3). Pathological features include 
atrophy and demyelination in the cauda equine and thinning of the sciatic and ulnar nerves, 
atrophy of the dorsal root ganglia (DRG), and significant loss of myelinated fibers in several 
afferent peripheral nerves (4). 
HSAN1 has been associated with mutations in six genes: SPTLC1 (5, 6), SPTLC2 (7), ATL1 
(8), DNMT1 (9), RAB7 (10) and ATL3 (11) . The majority of the identified HSAN1 patients 
carry mutations in SPTLC1 or SPTLC2. These genes encode for two out of three core 
subunits of serine-palmitoyltransferase (SPT). SPT is a pyridoxal phosphate (PLP) -
dependent α-oxoamine synthase (POAS) which catalyzes the condensation of palmitoyl-CoA 
and L-serine, the first and rate limiting step in the de novo synthesis of sphingolipids. 
Mammalian SPT is a heteromeric complex consisting of the ubiquitously expressed subunits 
SPTLC1 and SPTLC2, and the more tissue specific SPTLC3. All three subunits show a 
similarity on the amino acid level (12), but only SPTLC2 and SPTLC3 contain a PLP binding 
motif. The three SPT subunits interact in a tissue specific manner and probably form a 
hetero-octameric structure consisting of four active dimers (13).  
Initially, the HSAN1-locus was mapped to chromosome 9q22.1-q22.3 (14) and subsequently 
three point mutations in the SPTLC1 gene (p.C133W, p.C133Y and p.V144D) were found to 
be disease causing (5, 6). Later, four more SPTLC1 mutations (p.C133R, p.A352V, p.S331F, 
p.S331Y) (15-17) and mutations in SPTLC2 were reported to be disease causing (p.A182P, 
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p.G382V, p. V359M, p.S384F p.T409M and p.I504F) (20). Other mutations have also been 
reported but not conclusively linked to the disease yet. An SPTLC1 p.G387A variant was 
initially believed to cause a severe form of HSAN1 but was later demonstrated not to be 
disease-causing (21, 22). An SPTLC1 p.R239W variant was found in a large breast cancer 
screen (23) and an inactivating mutation (SPTLC1p.G246R) was identified in an SPT activity 
deficient CHO cell line (24, 25). Furthermore, an SPTLC1 p.R151L variant was annotated as 
a non-disease causing polymorphism in an HSAN1 patient with a mutation in the small 
GTPase RAB7 (26) and an SPTLC1 p.A339V mutation was identified in a German family 
with several affected individuals but showed an incomplete segregation pattern (unpublished 
data). An SPTLC2 p.T409M mutant was identified in an isolated patient but no other 
information about this patient was available to us. 
Typically, HSAN1 mutations cause a permanent shift in the substrate preference of SPT 
resulting in the use of the non-canonical amino acid substrates L-alanine and glycine, 
thereby forming the two atypical sphingoid bases 1-deoxy-sphinganine (1-deoxySA) and 1-
deoxymethyl-sphinganine (1-doxmethSA) (27). Both metabolites lack the C1 hydroxyl group 
of regular sphingoid bases, which precludes their metabolism to complex sphingolipids like 
sphingomyelins, hexosylceramides or gangliosides. The missing OH-group also hampers 
their degradation by the canonical catabolic pathway, as this requires phosphorylation at C1 
to form the catabolic intermediate sphingosine-1-phosphate (27). Pathologically increased 1-
deoxy-sphingolipid (1-deoxySL) levels were found in plasma and lymphoblasts of HSAN1 
patients (27, 28), representing a biochemical hallmark of HSAN1 but also a reliable 
biomarker for diagnosis.  
1-DeoxySLs are toxic to a variety of cell lines (29-32). Neurotoxicity was demonstrated in 
cultured primary chicken neurons (27, 33) and also reported from clinical phase I cancer 
studies in which 1-deoxySA was tested as a novel, experimental anti-cancer drug (34, 35). 1-
DeoxySA-induced cell death was shown to be associated with cytoskeletal changes and the 
disassembly of actin stress fibers, indicating that a deregulation of cytoskeletal structures 
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could be an underlying pathomechanism in HSAN1 (30). In fact, 1-deoxySLs were shown to 
alter cytoskeletal structures by activating the Rho – Rac pathways in beta cells (36). 
Mirroring its genotypic variability, HSAN1 is also characterized by phenotypic variability. 
Certain SPT mutants, like SPTLC1 p.V144D, were reported to be associated with rather mild 
symptoms whereas some other variants (SPTLC1 p.S331F and p.S331Y and SPTLC2 
p.I504F) cause a severe and early onset phenotype with anhydrosis, prominent muscle 
atrophy, growth retardation, ocular manifestations, and lung complications (15, 17, 37, 38).  
In this study we compared the enzymatic properties of 17 reported SPT mutants with the aim 
to provide a comprehensive characterization of these mutants and to see if there is a 
correlation between the enzymatic feature of the mutants and the variability in the HSAN1 
phenotypes.  
 
Materials and Methods: 
Ethical approval 
Ethical approval for the here used patient data was obtained by the respective local 
institutional review boards. Written informed consent was obtained from all patients.  
 
Generation of SPT mutants: 
Human SPTLC1 or SPTLC2 was cloned into pcDNA™3.1/V5-His (39) and modified by site 
directed mutagenesis as described earlier (20). To generate the mutants the following primer 
pairs were used: 
SPTLC1_C133W_FW 5′-GGGGACCCAGAGGATTTTATGGCACATTTGATGTTC-3′ 
SPTLC1_C133W_RV 5′-AGGTACCCACGCCA TACTTCTTTAGAGATGCTAAAGC-3′ 
SPTLC1_C133Y_FW  5′-ATGGTCCTCGAGGATTTTATGGCACATTTGATGTTC-3′ 
SPTLC1_C133Y_RV 5′-AGGTACCCACGCCA TACTTCTTTAGAGATGCTAAAGC-3′ 
SPTLC1_V144D_FW  5′-GTGGACCCAGAGGATTTTATGGCACATTTGATGATCATTTGGATTTGGAAGACCG-3′ 
SPTLC1_V144D_RV 5′-AGGTACCCACGCCA TACTTCTTTAGAGATGCTAAAGC-3′ 
SPTLC1_R151L_FW 5´-TTCATTTGGATTTGGAAGACCTCCTGGCAAAATTTATGAAGAC-3´ 
SPTLC1_R151L_RV 5´-GTCTTCATAAATTTTGCCAGGAGGTCTTCCAAATCCAAATGAA-3´ 
SPTLC1_R239W_FW 5´-CCTCGCAAGGCTCGTGTAACTTGGCGTTTCATT-3´ 
SPTLC1_R239W_RV 5´-AATGAAACGCCAAGTTACACGAGCCTTGCGAGG-3´ 
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SPTLC1_G246R_FW 5´-CGGCGTTTCATTGTAGTAGAACGATTGTATATGAATACTGGAA-3´ 
SPTLC1_G246R_RV 5´-TTCCAGTATTCATATACAATCGTTCTACTACAATGAAACGCCG-3´ 
SPTLC1_S331F_FW 5´-TGTAATTGACCATCAGCGACTTTTCGGCCAGGGATA-3´ 
SPTLC1_S331F_RV 5´-TATCCCTGGCCGAAAAGTCGCTGATGGTCAATTACA-3´ 
SPTLC1_S331Y_FW 5´-TGTAATTGACCATCAGCGACTTTACGGCCAGGGATA-3´ 
SPTLC1_S331Y_RV 5´-TATCCCTGGCCGTAAAGTCGCTGATGGTCAATTACA-3´ 
SPTLC1_A339V_FW 5´-GGGATACTGCTTTTCAGTAAGCTTACCTCCCCTGTTAGC-3´ 
SPTLC1_A339V_RV 5´-GCTAACAGGGGAGGTAAGCTTACTGAAAAGCAGTATCCC-3´ 
SPTLC1_A352V_FW 5´-TGCTGCAGCAATTGAGGTCCTCAACATCATGGAAG-3´ 
SPTLC1_A352V_RV 5´-CTTCCATGATGTTGAGGACCTCAATTGCTGCAGCA-3´ 
SPTLC1_G387A_FW 5′-AAGTGGTGGCGGAGTCCCTTTCTCCAGCCTTT CACCT-3′ 
SPTLC1_G387A_RV 5′-TTAATCCAGATATCCCTTGTAAAGCTTTAT GAATTTGTCC-3′ 
SPTLC2_A182P_FW 5´-CAACTATCTTGGATTTCCCCGGAATACTGGATCATG-3´ 
SPTLC2_A182P_RV 5´-CATGATCCAGTATTCCGGGGAAATCCAAGATAGTTG-3´ 
SPTLC2_V359M_FW 5´-CCACAGGCCGGGGTATGGTGGAGTAC-3´ 
SPTLC2_V359M_RV 5´-GTACTCCACCATACCCCGGCCTGTGG-3´ 
SPTLC2_G382V_FW 5´-GAACGTTCACAAAGAGTTTTGTTGCTTCTGGAGGATATATTGG-3´ 
SPTLC2_G382V_RV 5´-CCAATATATCCTCCAGAAGCAACAAAACTCTTTGTGAACGTTC-3´ 
SPTLC2_S384F_FW 5'-CAAAGAGTTTTGGTGCTTTCGGAGGATATATTGGAGGC-3' 
SPTLC2_S384F_RV 5'-GCCTCCAATATATCCTCCGAAAGCACCAAAACTCTTTG-3' 
SPTLC2_T409M_FW 5´-TAGTGCAGTGTATGCCATGTCATTGTCACCTCCTG-3´ 
SPTLC2_T409M_RV 5´-CAGGAGGTGACAATGACATGGCATACACTGCACTA-3´ 
SPTLC2_I504F_FW 5´-TTCCTGCCACCCCAATTTTTGAGTCCAGAGCC-3´ 
SPTLC2_I504F_RV 5´-GGCTCTGGACTCAAAAATTGGGGTGGCAGGAA-3´ 
 
All mutants and constructs were confirmed by sequencing.  
Cell Culture: 
HEK293 cells were cultured (37°C with 5% CO2) in Dulbecco’s modified Eagle’s medium 
(Sigma) with 10% fetal calf serum (Fisher Scientific FSA15-043), penicillin/streptomycin (100 
units per ml/0.1 mg per ml, Sigma) and 400μg/l G418 (Gibco). For storage, 5% of DMSO 
(Sigma) was added and cells were frozen in N2 liq. 
 
Transfection and expression: 
HEK293 cells (freshly obtained from the ATCC) were grown in 6-well dishes up to 80% 
confluence and transfected with Lipofectamine 2000 (Life Technologies) according to the 
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provided standard protocol. After two days cells were transferred to selection medium 
containing P/S and 400μg/l G418 (Gibco) and passaged a minimum of 3 times to establish 
stable cell lines.  
Expression of the transfected plasmids was confirmed by western blot using a combination of 
His- and V5-tag antibodies (Serotec).  
 
Metabolic labelling 
250’000 cells/well were seeded in 2ml fresh medium in 6-well plates (BD Falcon) and 
cultured for two days to reach ~70-80% confluence. The medium was exchanged for L-serine 
and L-alanine-free DMEM (Genaxxon Bioscience, Ulm, Germany), containing 10% FCS, P/S, 
and 400μg/ml G418. Two hours after medium exchange, isotope labeled d3-N15-L-serine 
(1mM) and (2,3,3,3)-d4-L-alanine (2mM) was added. In certain cases - Fumonisin B1 (FB1; 
10mg/ml in 100% EtOH) was also added to the cells (final concentration 35μM). After 24 
hours cells were harvested in 1ml cold PBS, counted (Beckman Coulter Z2), pelleted at 
800RCF @ 4°C, and stored at -20°C until further processing.  
 
Lipid extraction: 
Sphingoid bases in cells were analyzed from frozen cell pellets (2-3 million cells) re-
suspended in 100μl phosphate buffered saline (PBS) or directly from human EDTA plasma 
(100μl). Proteins were precipitated by adding 500µl MeOH (Honeywell), including 200 pmol 
internal standards (d7-SA and d7-SO, Avanti Polar Lipids, Alabaster CA) and lipids were 
extracted under constant agitation (1h, 1400rpm @ 37°C; Eppendorf Thermomixer Comfort; 
Eppendorf, Hamburg, Germany). Precipitated proteins were removed by centrifugation (5min 
@ 16100rcf, 22°C; Model 5415, Eppendorf, Hamburg, Germany) and the supernatant (500μl) 
was transferred to a new tube, followed by the addition of 75µl HCl (32%, Sigma). This 
mixture was incubated @ 65°C for 16h and finally neutralized by the addition of 100μl KOH 
[10M]. Hydrolyzed lipids were re-extracted by adding 125μl CHCl3, followed by the stepwise 
addition of another 500μl CHCl3, 100μl NH4OH [2N] and 500μl alkaline H2O in that order. 
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Samples were mixed thoroughly by vortexing between each step. Phases were separated by 
centrifugation at RT (13000g for 5min). The upper phase was removed and the lower phase 
washed twice with alkaline H2O (1ml). The remaining CHCl3 phase was evaporated under a 
flow of N2 (Techne Sample Concentrator, Bibby Scientific Ltd, Staffordshire, UK) and lipids 
were stored under N2 at -20°C. 
 
LC-MS 
For analysis, lipids were redissolved in 75μl derivatization mix (56.7% MeOH, 33.3% EtOH, 
10% H2O) and derivatized with 5μl of OPA working solution (990μl boric acid [3%] + 10µl ο-
Phthalaldehyde [50mg/ml in EtOH] + 0.5μl 2-Mercaptoethanol).  
Samples were separated for 30min on a reverse phase C18 column (Uptispere 120 Å, 5μm, 
125x2 mm, Interchim, France) with an isocratic mobile phase (1:1 methanol/ammonium 
acetate (5mM; Sigma) in water) at a flowrate of 400μl/min. After each run the column was 
regenerated for 10min with 100% MeOH.  
Spectra were recorded on a triple quad MassSpec (TSQ Quantum Ultra, Thermo Scientific) 
in positive mode using APCI ionization.  
 
Homology modelling and structural analysis: 
The human SPT model was generated using the homology-modelling server Swiss Model 
(http://swissmodel.expasy.org) (40-43). The subunits SPTLC1 and 2 were modelled 
separately based on the SPT structure from S. paucimobilis (PBD code 2JG2). The resulting 
models showed QMEAN4 values of -9.89 and -6.50 and GMQE values of 0.63 and 0.55, 
respectively. The modelled SPTLC1 and SPTLC2 comprise residues D51 to I464 and T163 
to G532, respectively. The dimer was built by aligning the modelled subunits onto the 
bacterial SPT (PBD code 2JGT) using Pymol. 
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Statistics 
Statistical significance was calculated by one way ANOVA and Dunnett’s multiple 
comparison test using GraphPad Prism 5. The principal component analysis was done in 
SIMCA-P+ (Umetrics). 
 
Results: 
HSAN1 mutations do not reduce canonical SPT activity 
In this study we compared the enzymatic and biochemical properties of 17 SPT mutants 
(Figure 1) in terms of activity and product spectrum. An overview of the analyzed mutations 
and their associated clinical phenotypes is summarized in Table 1. All constructs were 
expressed in HEK293 cells and expression was confirmed by western blot. SPT activity was 
analyzed in living cells using a metabolic labelling assay. For labelling, cells were cultured for 
24h in the presence of isotope labeled d3-N15-L-serine (1mM) and d4-L-alanine (2mM) in 
serine and alanine free medium. This results in d3-labelled sphingoid bases, as one 
deuterium is exchanged with a hydrogen during  condensation with palmitoyl-CoA. The total 
amount of de-novo formed sphingoid bases was analyzed after removing the conjugated N-
acyl chains and head groups by acid hydrolysis. In total seventeen sphingoid bases including 
C18SA, C18SO, 1-deoxySA, 1-deoxySO, C20SA and C20SO were quantified by LC-MS. 
The overexpression of wildtype SPTLC1 did not increase SPT activity compared to controls 
(empty vector), whereas overexpressing SPTLC2 resulted in a 2-fold increase in SPT activity 
(Figure 2A). Although reduced in-vitro activity was reported previously for several of the 
mutants (44-46), none of the SPTLC1 and SPTLC2 mutants showed a reduced incorporation 
of d3-N15-L-serine in our conditions. On the contrary, two SPTLC1 mutants (p.S331F and 
p.S331Y) and one SPTLC2 mutant (p.I504F) showed a significantly increased canonical 
activity. The 1-deoxySL formation in SPTLC1wt and SPTLC2wt overexpressing cells was 
comparable to controls (Figure 2B), indicating that the wild type SPT does not utilize 
significant amounts of L-alanine under these conditions. In contrast, several but not all SPT 
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mutants showed an increased 1-deoxySL formation. Significantly increased 1-deoxySL levels 
were seen in cells expressing the mutants STPLC1 p.C133W, p.C133Y, p.S331F, p.S331Y 
or SPTLC2 p.A182P, p.G382V, p.S384F and p.I504F. In contrast, the SPTLC1 variants 
p.V144D, p.G246R, p.A339V, and p.A352V and SPTLC2 p.V359M and p.T409M did not 
show significant activity with d4-L-alanine. 
Besides palmitoyl-CoA, SPT can also use other acyl-CoAs in the range of C14-C18, thereby 
forming sphingoid bases with different carbon chain lengths. Comparing the mutants for their 
ability to form sphingoid bases other than C18, we observed significantly increased C20 
sphingoid base levels in cells expressing the mutants SPTLC1 p.S331F, p.S331Y and 
SPTLC2 p.I504F (Fig. 2C). C20 sphingoid bases are formed by the conjugation of stearyl-CoA 
and L-serine, and increased levels of these sphingoid bases have not yet reported in the 
context of HSAN1. An increased C20 sphingoid base formation was only seen for this 
particular subclass of HSAN1 mutants.  
Interestingly, the activity pattern of the mutants changed in the presence of the mycotoxin 
fumonisin B1 (FB1), a potent inhibitor of ceramide synthase (CerS). CerS catalyzes the 
acylation of sphinganine to dihydro-ceramide – the subsequent step in the de-novo synthesis 
pathway. Blocking CerS by FB1 leads to an accumulation of the precursor sphinganine (47) 
and was reported previously to increase 1-deoxySA formation in cells (29). The addition of 
FB1 induced significant changes in the canonical activity of the mutants. While SPT activity 
in SPTLC1 p.V144D, p.A339V and p.G387A expressing cells was comparable to controls, 
cells expressing the mutants SPTLC1 p.C133W, p.C133Y, p.R239W, p.G246R and p.A352V 
showed a significantly reduced activity in the presence of FB1 (Fig. 2D). The activity of 
SPTLC2 p.A182P, p.V359M, p.G382V and p.S384F was also reduced compared to wild type 
SPTLC2, whereas the activity of SPTLC2 p.T409M was not altered. Interestingly, those 
mutations which initially had an increased canonical activity (SPTLC1 p.S331Y/F; SPTLC2 
p.I505F) showed a more pronounced reduction in activity in the presence of FB1. In contrast, 
the pattern of 1-deoxySL formation was not changed in the presence of FB1 (Fig. 2E). 
However, certain mutants showed a several fold increase in 1-deoxySL levels in the 
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presence of FB1. For SPTLC1p.C133W and p.C133Y, 1-deoxySL formation increased 4.5- 
and 2.3-fold, respectively, whereas this effect was less pronounced for SPTLC1p.S331F and 
p.S331Y (1.3- and 1.8-fold, respectively). SPTLC2p.I504F and p.A182P showed a 4- and 10- 
fold increase in 1-deoxySL formation, respectively. 
The formation of 1-deoxySLs is modulated by the availability of L-serine and L-alanine (48). 
1-DeoxySL formation was effectively suppressed in an HSAN1 mouse model by L-serine 
enriched food  which was shown to protect the animals from developing neurological 
symptoms (48). A significant reduction of plasma 1-deoxySL levels was also observed in 
HSAN1 patients who received oral supplementation with L-serine in the context of a clinical 
pilot trial (48). In contrast, increased availability of L-alanine resulted in augmented 1-
deoxySL formation and aggravated neuropathic symptoms in the HSAN1 mouse model (48). 
We therefore compared the effect of L-serine and L-alanine on a set of selected mutants 
(Figure 2F+G). At 10mM L-serine we observed a slightly increased canonical activity in all 
cells, although this increase was significantly more pronounced in cell expressing the 
p.S331F mutant (Figure 2F). In parallel, 1-deoxySL formation was greatly suppressed at 
elevated L-serine levels whereas 10mM alanine significantly stimulated 1-deoxySL formation 
in all mutant-expressing cells (Figure 2G). No significant increase in 1-deoxySL formation 
was seen in SPTLC1wt and SPTLC2wt overexpressing cells in the presence of 10mM 
alanine. Except for a slight stimulatory effect in SPTLC2 p.A182P expressing cells, L-alanine 
had no significant influence on the canonical activity of SPT.   
 
Activity of HSAN1 mutants in LYB cells 
All previous experiments were performed in HEK293 cells on the background of the 
endogenously expressed wildtype SPT. Although this mirrors the dominant trait in HSAN1, it 
does not allow for analyzing the residual activity of the mutants. We therefore tested the 
mutants in LYB cells, a CHO cell line which is deficient in endogenous SPT activity due to a 
spontaneous mutation in the SPTLC1 subunit. The mutation was subsequently identified as 
SPTLC1p.G246R. Expressing a functional wildtype SPTLC1 is sufficient to restore SPT 
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activity in these cells (24, 25).  We used LYB cells to compare the activity of SPTLC1wt, 
p.C133W, pG246R, S331F in the presence and absence of FB1 (Fig.3). As controls we also 
expressed SPTLC2wt and p.I504F in these cells, although it is not expected that this results 
in a recovery of enzyme activity, as the underlying mutation is located in the SPTLC1 
subunit. Accordingly, the expression of wildtype SPTLC1 but not of SPTLC2 restored activity 
(Fig.3). Expressing the mutant p.C133W restored canonical activity only marginally, and 
activity was further reduced in the presence of FB1. Interestingly, the capacity to form 1-
deoxySLs remained intact in this mutant, indicating that the mutation primarily affects the 
activity with L-serine. Like expected,  expression of p.G246R, which is the same mutation 
that is present in LYB endogenously, neither restored canonical activity nor resulted in the 
formation of 1-deoxySLs.  In contrast, expression of the p.S331F mutant fully restored 
canonical activity, and in fact the activity was even 9-10 fold higher compared to the wt 
subunit. Activity with alanine was also present and 1-deoxySL formation was about 2-fold 
higher compared to p.C133W cells. However, in the presence of FB1, canonical activity of 
the p.S331F dropped greatly, whereas 1-deoxySL formation was increased by 30%. Similar 
to the expression of the wildtype SPTLC2, the expression of p.I504F was not able to restore 
activity in LYB cells.  
 
Genotype-phenotype association in HSAN1 
To further stratify the biochemical properties of the tested mutants, we performed a principal 
component analysis (PCA) for all 20 constructs (17 mutants, 2 wildtype subunits, and control 
cells). As variables we included the ratios (mut:wt) for de-novo formed d3-C17SO; d3-
sphingadiene; d3-C18SA; d3-C18SO; d3-C20SO; d3-deoxySA and d3-deoxySO. This 
generated two principal components which separated the mutants into three isolated clusters 
(Fig. 4A). As expected, the assigned discriminatory weight for the suggested model identified 
the two 1-deoxySL species and C20SO as the strongest discriminators for the clustering (Fig. 
4B). Strikingly, the three clusters perfectly mirrored the associated clinical HSAN1 
phenotypes. The 1st group comprised all mutations which showed no change in canonical 
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activity (in the absence of FB1). In the metabolic labelling assay these variants behaved 
similarly to the respective wild type subunits and did not form increased levels of 1-deoxySLs 
nor C20-sphingoid bases. This cluster is not associated with a disease phenotype. 
The 2nd cluster included mutations that were associated with increased 1-deoxySL formation 
but an unaltered canonical activity. The 2nd group comprised the mutations SPTLC1 
p.C133W and p.C133Y and SPTLC2 p.A182P, p.G382V and p.S384F. These mutations are 
associated with a typical late onset HSAN1 phenotype, with primarily sensory and mild motor 
impairments. Within this cluster, the SPTLC1 p.C133Y and p.C133W are the most frequently 
found mutations in HSAN1 and appear in several large kinships in Europe, US and Australia. 
Also the three SPTLC2 mutations p.G382V, p.S384F and p.A182P were reported to be 
associated with a rather typical HSAN1 phenotype. 
The 3rd cluster consisted of three mutants (SPTLC1 p.S331F, p.S331Y and SPTLC2 
p.I504F). This group was characterized by an increased formation of C18-, 1-deoxy- and C20-
sphingoid bases. In particular, the increased formation of C20-based sphingolipids is a unique 
hallmark of this group. These three mutations are associated with an exceptionally severe 
HSAN1 phenotype characterized by early or even congenital onset, growth retardation, 
autonomic impairments (sweating), motor neuron defects, juvenile cataracts, and weakness 
in the respiratory system. Plotting the ratios of C18 SO, 1-deoxySL and C20SL in the individual 
mutants relative to the wt subunit resulted in a similar clustering as seen in the PCA (Fig. 
4C). Furthermore, a similar clustering was also observed when analyzing the sphingoid 
bases in plasma samples from HSAN1 patients (Fig. 4D). Unfortunately, plasma samples 
were only available for seven out of the 17 analyzed mutations. No difference in canonical 
C18 sphingoid bases was seen in any of the analyzed plasma samples.  Mirroring the results 
from the cell culture experiments, SPTLC1 p.C133W, p.C133Y, and p.V144D carriers 
presented with elevated 1-deoxySL levels and unchanged C20SL levels. Also in line with the 
cell culture experiments we observed clearly elevated 1-deoxySL and C20-sphingoid bases in 
plasma from p.S331Y/F carriers. Plasma from an I505F carrier was not available. The 
plasma of an SPTLC1 p.R151L carrier analyzed here for the first time did not show increased 
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1-deoxySL neither altered C18SL or C20SL levels, indicating that this mutation is not disease-
associated. 
 
Structure - function relationship 
In continuation of the biochemical analysis we wanted to see if the biochemical features of 
the different HSAN1 mutants can be mapped onto specific regions of the protein. To this 
purpose we generated a homology model for the human SPT dimer based on the prokaryotic 
SPT structure from S. paucimobilis (PBD entry code 2JG2). Like the functional analysis,  the 
structural analysis also assigned the mutants into three distinct groups. The first group 
comprised all mutants that could not be assigned to any specific structural cluster (Fig. 5A). 
This first group did not show altered SPT activity nor significant 1-deoxySL formation, and 
corresponds to cluster 1 in Fig. 4A (blue). Most amino acid exchanges within this group are 
conservative and the expected structural impact for these mutations is minor except for 
SPTLC2 p.T409 which is prominently located at the interface between SPTLC1 and 
SPTLC2. However, whether an exchange from T to the more polar M has an impact on the 
interaction of the subunits is difficult to assess. The second group comprised the residues 
SPTLC1 p.C133, SPTLC2 p.A182, p.G382, and p.S384, which are all located around the 
internal aldimine in SPTLC2 (Figure 4B). This group corresponds to cluster 2 (green) in Fig. 
4A and is associated with normal canonical activity but increased 1-deoxySL formation. 
Residue p.C133 is part of SPTLC1 which by itself does not bear a PLP binding site, but is 
located close to the internal aldimine of the SPTLC2 subunit. A change to W and Y is 
expected to have an impact on activity, probably by modifying the binding properties of the 
incoming substrates. The mutant SPTLC2 p.A182P might alter the flexibility of the PLP 
region, having also a significant impact on the binding of the substrates. The SPTLC2 
p.S384F mutation is likewise supposed to alter the activity of the protein. The impact of the 
SPTLC2 p.G382V mutation is more difficult to estimate, as the exchange from G to V 
conserves the physicochemical properties of the residue. However, this replacement may 
influence the dynamics of the loops surrounding the active site. Except for the SPTLC1 
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p.A339V, all these variants were associated with reduced canonical activity in the presence 
of FB1. Based on the position, the A339V mutation could also be assigned to cluster 2, but 
was functionally classified into cluster 1 as it was not associated with increased 1-deoxySL 
formation. The third group comprised two residues exposed at the surface of the protein, 
SPTLC1 p.S331 and SPTLC2 p.I504 (Fig. 5C). Mutations in the residues S331 and I504 
were grouped into cluster 3 (red in Fig 3A) and are associated with increased canonical 
activity as well as increased 1-deoxySL and C20SO formation. Residues R151 and V144 are 
also located on a surface-exposed helix (Fig. 4C, light blue) following the active site loop 
carrying C133. However, functionally residues R151 and V144 do not cluster into group 3 as 
they are clearly not associated with the same severe features as seen for S331F/Y and 
I504F. Indeed both mutants did not show significantly altered activities in our analysis, 
although the V144A was reported repeatedly to be associated with HSAN1.  
Discussion:  
Here we compared seventeen SPT mutants for their enzymatic activity and substrate affinity. 
The majority of the analyzed variants were identified in patients with HSAN1. Using a 
metabolic labeling approach, we analyzed SPT activity and SL de-novo synthesis in an intact 
cellular context.  
None of the analyzed mutants showed a reduced formation of canonical C18 sphingoid 
bases, indicating that HSAN1 is not caused by a loss of activity as initially proposed (44, 45, 
49). In contrast, three mutants showed an increased ability to form canonical C18 - as well as 
atypical C20 sphingoid bases (Fig. 2C). Elevated C20 sphingoid bases were also found in the 
plasma of patients with these mutations (Fig. 4C). Most HSAN1 mutants showed a 
significantly increased activity with alanine, leading to increased 1-deoxySL formation. 
However, two reported mutations in SPTLC1 (p.A339V, p.A352V) and SPTLC2 (p.T409M, 
p.V359M) did not match this pattern. SPTLC1 p.A352V and SPTLC2 p.V359M were already 
suggested previously not to be disease causing (7, 17), whereas SPTLC1 p.A339V and 
SPTLC2 p.T409M were not yet characterized. The SPTLC1 p.A339V variant was found in a 
German patient who suffered from idiopathic neuropathy, but further sequencing of affected 
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and non-affected family members revealed an incomplete segregation of this mutation within 
the family. For the SPTLC2 p.T409M carrier no clinical information was available. Both 
mutants seem to be benign as neither was associated with altered canonical activity or 
significantly increased 1-deoxySL formation, although SPTLC1 p.A339V showed slightly 
increased 1-deoxySL formation in high alanine conditions (Fig.2G). 
Surprisingly, the CerS inhibitor FB1 showed significant effects on the activity of some but not 
all mutants, although FB1 does not directly affect SPT activity. Several mutants (SPTLC1 
p.C133W, p.R151L, p.R239W, p.G243R, p.S331F, p.A352V, and SPTLC2 p.G382F) had a 
reduced canonical activity in the presence of FB1. This FB1-dependent change in canonical 
activity was most obvious in SPTLC1 p.S331F-expressing LYB cells (Fig. 3A). In the 
presence of FB1, the activity pattern of the mutants generally resembled the pattern reported 
from cell free in-vitro assays. A reduced in-vitro activity was previously reported for several of 
these mutants (44, 45, 49). Except for p.S331F/Y, most of the FB1-sensitive mutations are 
located in a cluster around the PLP binding site (Fig.5 B). Surprisingly, the ability to form 1-
deoxySLs did not change in the presence of FB1. However, for some mutants absolute 1-
deoxySL levels were up to 10-fold higher in the presence of FB1, which is supported by 
earlier reports showing that FB1 stimulates the formation of 1-deoxySLs even in wild type 
SPT (29). Expression of the mutants in LYB cells indicates that the activity with L-serine and 
L-alanine is independent and not directly linked. In general we did not see a significant 
correlation between the formation of canonical SLs and 1-deoxySLs, either in mutant- 
expressing cells or in patient plasma. This shows discordance between canonical SPT 
activity and 1-deoxSL formation, meaning that the use of 1-deoxySLs as surrogate markers 
for SPT activity can lead to inappropriate interpretation of the canonical activity (50). 
The observed differences in the presence of FB1 might be caused by a disturbance of the 
cellular mechanisms that regulate SL de-novo synthesis. SPT activity seems to be tightly 
controlled by a metabolic feedback mechanism which counteracts the potentially harmful 
overproduction of ceramides. In yeast, this process is well understood and includes 
accessory proteins like Orm1/2, Sac1 and Tsc3 which form a higher order complex called 
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SPOTS (serine palmitoyltransferase, Orm1/2, Tsc3 and Sac1) (51). At sufficient SL levels, 
Orm1/2  associate with the complex and inhibit SPT activity. Upon SL shortage, Orm1/2 
become gradually phosphorylated by Ypk1 kinase and, together with Sac1, dissociate from 
the complex thereby releasing inhibition (51, 52). Once SL levels are restored, Orm proteins 
get dephosphorylated again. As FB1 blocks the formation of products downstream of SA, this 
regulatory control might be eluded. However, it is unclear to which extent the same 
mechanism applies to higher eukaryotes. Mammalian cells express three ORM orthologues 
(ORMDL1-3) (53), but the Orm1/2 phosphorylation sites identified in yeast are not 
conserved. Individual or simultaneous overexpression of the ORMDL proteins has no effect 
on SPT activity, whereas the parallel silencing of all three but not of the individual ORMDL 
isoforms was reported to increase SPT activity (54). Furthermore, two small proteins 
(ssSPTa and ssSPTb) were identified in mammalian cells as functional orthologues of the 
yeast Tsc3 (55). Co-expression of the SPT core subunits SPTLC1 and 2 together with 
ssSPTa or ssSPTb was shown to increase SPT activity and to modulate the acyl-CoA 
preference of SPT. In our analysis we observed an increased canonical activity for three 
mutants (SPTLC1 p.S331F, p.S331Y and SPTLC2 p.I504F). Strikingly, the orthologous 
mutations in yeast were reported earlier to compensate for Tsc3 deficiency. In 2002 
Monaghan found that the yeast mutant LCB1 p.I491F (the orthologue of SPTLC2 p.I504F) 
can compensate for the lack of Tsc3 (56). Han and colleagues showed that the activation of 
SPT by the small subunits was altered for certain SPTLC2 mutations and that co-expressing 
the SPTLC1 p.S331F mutant with SPTLC2 enabled a yeast SPT knockout strain to grow 
without the need for additional activation by ssSPTa (57). This suggests that these mutations 
influence the interaction of SPT with regulatory subunits like ssSPTa and b. Accordingly, we 
found that canonical activity as well as 1-deoxy- and C20SL formation increased in cells 
expressing SPTLC1 p.S331F/Y or SPTLC2 p.I504F mutants. Interestingly, the residues 
SPTLC1 p.S331 and SPTLC2 p.I504 are both located on the surface of the protein (Fig 4A), 
suggesting that the apparent dysregulation of these mutants could be due to an impaired 
interaction with the small subunits ssSPTa or ssSPTb.  A recently published paper reported 
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that a mutation in ssSPTb is associated with increased C20SL production and 
neurodegeneration in mice (58).   
Clinical symptoms of patients carrying the SPTLC1 p.S331F/Y or SPTLC2 p.I504F mutation 
are clearly distinct from other HSAN1 cases. These variants are characterized by an early or 
congenital onset of symptoms, severe muscular impairments, growth retardation, early 
cataracts, and impairments of the respiratory system (15, 38). Motor neurons seem to be 
more dominantly affected in these patients compared to carriers of milder HSAN1 mutations 
who predominantly have sensory symptoms. We assume that the distinct clinical symptoms 
are directly related to the biochemical features in these mutants, although the mechanism by 
which they affect disease pathology remains to be determined. It is feasible that increased 
ceramide formation in cells expressing these variants causes, in addition to elevated 1-
deoxySLs, further neurotoxic insults. However, total C18 SL levels were not elevated in 
plasma of these patients, although this does not exclude elevated ceramide levels in certain 
cells and tissues, including peripheral neurons or Schwann cells. Unfortunately no biopsy 
material from these patients was available for comparison of ceramide levels between 
tissues.  
The pathological formation of 1-deoxySLs is a hallmark of HSAN1, and plasma 1-deoxySL 
levels correlate significantly with disease severity (59). The HSAN1 mutations SPTLC1 
p.C133W, p.C133Y and also the recently found SPTLC2 mutations p.A182P, p.G382V and 
p.S384F are robustly associated with an increased 1-deoxySL formation, whereas mutations 
found in a non-HSAN1 context (like the SPTLC1 p.R151L or p.G382V) do not form 1-
deoxySLs.   
Although most analyzed HSAN1 mutants coincided with this observation, there is one 
exception which is the SPTLC1 p.V144D mutant. In cell culture the p.V144D showed no 
significant 1-deoxySL formation. However, the p.V144D mutation was one of the first two 
annotated HSAN1 mutations, and patients bearing this mutation present with elevated 1-
deoxySL plasma levels and an HSAN1 phenotype. The reason for this discrepancy is not 
clear but indicates that additional, not yet characterized systemic factors could influence 1-
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deoxySL formation, which might not be fully recapitulated in the cell based assays. 
Independent of the type of mutation, 1-deoxySL formation was greatly reduced at elevated 
serine levels (Fig 2G). In contrast, 1-dexoySL formation was significantly increased at 
elevated alanine levels. This indicates that L-serine supplementation could be a potential 
treatment for any form of HSAN1, irrespective of the underlying mutations.  
In conclusion we showed that mutations in SPT are functionally heterogeneous. Three 
different biochemical phenotypes are directly associated with three different clinical 
presentations: no HSAN1, late-onset and moderate HSAN1, or early-onset and severe 
HSAN1. A more detailed understanding of the underlying structure-function-phenotype 
relationships is necessary to also mechanistically link these biochemical differences to 
pathomechanisms. 
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Figure Legends: 
 
Figure 1: Overview of the seventeen SPTLC1 and SPTLC2 mutations analyzed. The color 
code is the same as for the cluster and structural analysis in Fig. 4 and 5. Cluster 1 – blue; 
Cluster 2 – green; Cluster 3 - red 
 
Figure 2: De-novo formation of C18 sphinganine (d3-C18SA) and C18 sphingosine (d3-
C18SO) (A); 1-deoxySA (d3-deoxySA) and 1-deoxySO (d3-deoxySO) (B);  and C20 
sphingosine (d3-C20SO) (C) in mutant-expressing HEK293 cells within 24h.  
De-novo formation of C18 sphinganine (d3-C18SA) and C18 sphingosine (d3-C18SO) (D) and 
of 1-deoxySA (d3-deoxySA) and 1-deoxySO (d3-deoxySO) (E) in the presence of Fumonisin 
B1 (35μM). Cells were transfected with the empty vector (empty), SPTLC1wt, SPTLC2wt or 
the individual HSAN1 mutations, and cultured in the presence of d3-N15-L-serine (1mM) and 
d4-L-alanine (2mM), respectively.   
De-novo formation of canonical SLs (F) and 1-deoxySLs (G) in relation to the availability of 
serine and alanine. HEK 293 cells expressing the SPTLC1wt, p.S331F, p.A339V or 
SPTLC2wt, p.A182P, I504F were cultured for 24 hours at different concentrations of d3-L-
serine and d4-L-alanine (1mM Ser/2mM Ala, 10mM Ser/2mM Ala and 1mM Ser/10mM Ala). 
Labeled sphingoid bases were quantified by LC-MS after hydrolysis. Statistical significance 
was calculated by one-way ANOVA followed by Dunnetts multiple comparison test. * p<0.01; 
** p< 0.001; *** p<0.0001.  
 
Figure 3: De-novo formation of (A) C18 sphinganine (d3-C18SA) and C18 sphingosine (d3-
C18SO) and (B) 1-deoxySA (d3-deoxySA) and 1-deoxySO (d3-deoxySO) in mutant-
expressing LYB cells.  Activity was tested in the presence and absence of Fumonisin B1. 
Labeled sphingoid bases were quantified by LC-MS after hydrolysis. ** p< 0.001; *** 
p<0.0001 
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Figure 4 (A) Score scatter plot of a principal component analysis (PCA) based on the ratios 
mut:wt for C17SO, SAdiene, C18SA C18SO, C20SO, 1-deoxySA and 1-deoxySO (blue: Cluster 
1, green: Cluster2, red: Cluster 3); R2X[1] = 0.79 R2X[2] = 0.15.  (B) Loading scatter plot of 
the PCA. Distance and direction from the origin of the axes equals the assigned weight and 
importance of the individual sphingolipid species for the grouping of the mutants. 
(C) Clustering of the different HSAN1 mutations based on their activity in forming C18SL, 
C20SL and 1-deoxySL. Shown are the ratios (wt:mutant) of de-novo formed (deoxy)sphingoid 
bases in mutant-expressing HEK293 cells which were cultured for 24h in the presence of d3-
N151-L-serine (1mM) and d4-L-alanine (2mM).  (D) Clustering of the different HSAN1 
mutations based on the levels for C18SL, C20SL and 1-deoxySL in plasma samples from 
patients. The figure is based on previously published plasma data from HSAN1 patients (7, 
15, 17, 19, 20, 27, 60). The depicted numbers reflect the underlying mutation (triangle - 
SPTLC1, circle - SPTLC2). Identical numbers reflect the same mutation from different 
patients. 
Figure 5: Homology model of the human SPTLC1-SPTLC2 dimer, colored white and dark 
gray respectively. (A) The mutations analyzed in this work are depicted. The residues 
belonging to SPTLC2 are marked with an asterisk. The color code is identical to Fig.4A. (B) 
Most of the mutations associated with a typical HSAN1 phenotype are located at the 
monomer-monomer interface and cluster around the PLP binding domain. (C) The two 
residues SPTLC1 p.S331 and SPTLC2 p.I504F are located far away from the PLP binding 
site on the surface of the protein. Mutations in these residues are associated with a severe 
phenotype. All figures were prepared with Pymol. Mutations located in the SPTLC2 subunit 
are depicted with an *. 
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Mutation 
origin/ 
inheritance 
AAO 
(years) 
type of 
polyneuropathy 
weaknes
s 
ulcers/ 
amputati
on 
respirato
ry 
problem
s 
catarac
ts 
(age) 
other symptoms 
Reference 
(Author, 
year) 
SPTLC1 
p.C133W 
Australian 
English/NM 
65 NM 
Yes in 
4/38 
Yes NM NM NS 
Dawkins et 
al, 2001 
SPTLC1 
p.C133W 
Canadian/N
M 
20-40 NM 
Yes in 
6/7 
Yes NM NM 
NS Bejaoui et 
al, 2001 
SPTLC1 
p.C133W 
Chinese/AD 20's sensory motor No Yes NM NM 
NS Bi et al, 
2007 
SPTLC1 
p.C133W 
Canadian/A
D 
12, 60's sensory 
peroneal 
atrophy 
Yes NM NM 
NS Klein et al, 
2005  
SPTLC1 
p.C133W 
English/AD 
and IC 
12 – 70, 
Avg=29 
sensory motor Yes Yes NM NM 
NS Houlden et 
al, 2006 
SPTLC1 
p.C133Y 
German/NM NM NM NM NM NM NM 
NS Bejaoui et 
al, 2001 
SPTLC1 
p.C133Y 
Australian 
German/NM 
NM NM NM NM NM NM 
NS Dawkins et 
al, 2001 
SPTLC1 
p.C133Y 
Portuguese/
AD 
20's, 10 sensory motor No No NM No 
Foot pain, dry 
skin 
Geraldes et 
al, 2004  
SPTLC1 
p.C133R 
German/AD 50 None No NM NM NM 
NS Rautenstrau
ss et al, 
2009 
SPTLC1 
p.V144D 
Australian 
German/NM 
NM NM NM NM NM NM 
NS Dawkins et 
al, 2001 
SPTLC1 
p.A310G 
English/IC 50's sensory No Yes NM NM 
NS Davidson et 
al, 2012 
SPTLC1 
p.S331F 
German/IC 
Early 
childhood 
sensory motor Yes Yes NM Yes (9) 
sweating 
disturbances 
and anhydrosis, 
joint 
contractures, 
fractures 
Huehne et 
al, 2008 
SPTLC1 
p.S331F 
French 
(Gypsy)/IC 
congenital sensory motor Yes Yes Yes Yes 
joint hyperlaxity, 
severe growth 
and mental 
Rotthier et 
al, 2009 
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Table 1: Overview of clinical features of HSAN1 patients with SPTLC1 mutations (combined 
and adapted from (7, 15, 38)) AAO, age at onset; PN, polyneuropathy; IC, isolated case; SM, 
sensory motor polyneuropathy; NM, not mentioned; AD, autosomal dominant; IC, isolated 
case; LL, lower limbs; UL, upper limbs; NS, not specified
retardation, 
microcephaly, 
hypotonia, vocal 
cord paralysis, 
gastro-
oesophagial 
reflux 
 
Korean/IC 5 sensory motor 
Yes 
walker 
(27)a 
Yes Yes 
Yes 
(10) 
Hoarseness, 
tremor, scoliosis 
Suh et al. 
2014 
SPTLC1 
p.S331Y 
Austria/IC 4 sensory motor 
Yes 
wheelch
air (14)a 
Yes Yes 
Yes 
(13) 
Tremor, 
fasciculation,  
joint 
hypermobility, 
pes cavus 
Auer-
Grumbach 
et al, 2013 
SPTLC1 
p.A352V 
Austrian/IC 16 sensory motor 
, distal 
LL, 
peroneal 
atrophy 
No NM NM 
Mild pes cavus, 
lancinating 
pains 
Rotthier et 
al, 20009 
SPTLC2 
p.V359M 
Austrian/IC 52 yrs 
axonal/intermedi
ate  
sensory motor 
NM 
Yes 
/great R 
toe 
NM NM 
ulceration and 
amputation of 
great  R toe 
Rotthier et 
al, 2010 
SPTLC2 
p.G382V 
German/D 37yrs 
axonal/intermedi
ate  
sensory motor 
Yes UL 
and LL 
No NM NM 
dysesthesia and 
sensory loss 
distal UL and LL 
Rotthier et 
al, 2010 
SPTLC2 
p.G382V 
Austrian/D 
38 yrs, 
mother 
asymptoma
tic 
axonal sensory 
motor 
Yes LL No NM NM 
sensory loss in 
feet 
Rotthier et 
al, 2010 
SPTLC2 
p.I504F 
Czech/IC 
(de novo) 
5 yrs 
intermediate 
sensory motor 
Yes (LL) Yes (LL) NM NM 
sweating 
disturbances 
and anhydrosis, 
gait difficulties, 
foot deformities 
Rotthier et 
al, 2010 
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